HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia

Research output: Contribution to journalReview articlepeer-review

664 Scopus citations


THE recent introduction of a unique class of cholesterol-lowering drugs offers new promise for the treatment of hypercholesterolemia. These drugs are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the synthesis of cholesterol. Relatively low doses of these agents will reduce plasma cholesterol levels markedly, and in short-term studies, they have not been found to produce serious side effects. Thus, in 1987 the Food and Drug Administration approved one HMG-CoA reductase inhibitor — lovastatin. If reductase inhibitors prove to be free of long-term adverse effects, they will undoubtedly be used widely for treating hypercholesterolemia. This review will examine.

Original languageEnglish (US)
Pages (from-to)24-33
Number of pages10
JournalNew England Journal of Medicine
Issue number1
StatePublished - Jul 7 1988

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia'. Together they form a unique fingerprint.

Cite this